NCT06309953

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Detailed description

The primary objective of this study is to evaluate early outcomes with Miebo treatment in subjects with Dry Eye Disease (DED)

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	Miebo	Miebo® (perfluorohexyloctane ophthalmic solution) Dosage: one drop of MIEBO four times daily into each eye Dosage form: Ophthalmic solution: 100% perfluorohexyloctane. Frequency: 4 times daily for 14 days

Timeline

• Start date: 2024-02-28
• Primary completion: 2024-06-17
• Completion: 2024-06-17
• First posted: 2024-03-13
• Last updated: 2025-10-21
• Results posted: 2025-10-21

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study